Lurbinectedin - Generic Drug Details

What are the generic sources for lurbinectedin and what is the scope of freedom to operate?

Lurbinectedin is the generic ingredient in one branded drug marketed by Jazz and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lurbinectedin has sixty-three patent family members in thirty-four countries.

One supplier is listed for this compound.

Summary for lurbinectedin

International Patents:	63
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	49
Patent Applications:	664
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for lurbinectedin
What excipients (inactive ingredients) are in lurbinectedin?	lurbinectedin excipients list
DailyMed Link:	lurbinectedin at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for lurbinectedin

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lurbinectedin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	PHASE1
AbbVie	PHASE2
Misty Shields	PHASE1

See all lurbinectedin clinical trials

Pharmacology for lurbinectedin

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Anatomical Therapeutic Chemical (ATC) Classes for lurbinectedin

L01XX	Other antineoplastic agents
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for LURBINECTEDIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZEPZELCA	Powder for Injection	lurbinectedin	4 mg/vial	213702	5	2024-06-17

US Patents and Regulatory Information for lurbinectedin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes			Y	Y
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes
Jazz	ZEPZELCA	lurbinectedin	POWDER;INTRAVENOUS	213702-001	Jun 15, 2020		RX	Yes	Yes

International Patents for lurbinectedin

Country	Patent Number	Title	Estimated Expiration
Israel	322021	שיטות לטיפול בסרטן התאים הקטנים של הריאה באמצעות פורמולציות לורבינקטדין (Methods of treating small cell lung cancer with lurbinectedin formulations)
Hong Kong	1065786
Austria	374777
Saudi Arabia	522432668	طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين (METHODS OF TREATING SMALL CELL LUNG CANCER WITH LURBINECTEDIN FORMULATIONS)
Colombia	2022008437

Market Dynamics and Financial Trajectory for Lurbinectedin

Last updated: July 29, 2025

Introduction

Lurbinectedin (Brand Name: Zepzelca) is an oncology drug developed by pharma giant Pharma Mar, which garnered significant attention upon its FDA approval in June 2020 for relapsed small cell lung cancer (SCLC). Recognized as an innovative transcription inhibitor derived from marine natural products, lurbinectedin's market presence exemplifies the complex interplay of clinical efficacy, regulatory landscape, competitive dynamics, and evolving healthcare strategies. This article explores the current market landscape, future growth drivers, and financial trajectory prospects of lurbinectedin within the broader oncology therapeutics market.

Market Overview and Indications

Lurbinectedin's primary indication is for adult patients with relapsed extensive-stage small cell lung cancer (ES-SCLC), a notoriously aggressive and difficult-to-treat malignancy [1]. The drug’s approval was based on clinical trial data demonstrating meaningful response rates and survival benefits in a patient population with limited treatment options.

While its initial market role is niche, its approval paves the way for positioning within a broader scope of solid tumors and hematologic malignancies—potential indications that ongoing trials aim to address. Notably, its mechanism—targeting the tumor microenvironment and transcription machinery—might translate into efficacy across other cancer types, signaling an expandable market.

Market Dynamics

1. Competitive Landscape

Lurbinectedin faces competition from established chemotherapeutic agents as well as emerging targeted therapies and immunotherapies used in SCLC and related cancers. While topotecan remains a standard in relapsed SCLC, recent advances such as the introduction of immune checkpoint inhibitors like atezolizumab and durvalumab have shifted treatment paradigms [2].

Moreover, the oncology pipeline features numerous novel agents, including second-line agents and combination regimens, potentially impacting lurbinectedin's market share. Its advantage lies in demonstrating activity in patients with refractory disease and a tolerable safety profile, which could secure its niche within second- or third-line therapy settings.

2. Regulatory and Reimbursement Challenges

Despite FDA approval, the drug's commercial uptake hinges on reimbursement policies, healthcare provider acceptance, and the competitive landscape of third-line therapies. Payer negotiations and cost-effectiveness assessments influence market penetration considerably, especially given the relatively high price point typical of targeted oncology agents.

Recent health technology assessments (HTAs) by payers such as the NHS or CMS in the US could pose hurdles unless compelling real-world evidence supports the drug's cost-benefit profile.

3. R&D and Clinical Development

Pharma Mar's strategic investments into broader indications for lurbinectedin could significantly influence its market trajectory. Clinical trials investigating lurbinectedin in combination with other agents for ovarian cancer, breast cancer, and mesothelioma promise to expand its application scope.

An example is the phase II trial assessing lurbinectedin combined with doxorubicin in metastatic breast cancer, which could unlock new revenue streams if successful [3].

4. Market Penetration and Adoption Factors

The speed and extent of adoption depend on factors such as the drug’s real-world safety profile, ease of administration, positioning within treatment algorithms, and clinician familiarity. Educational efforts and evidence dissemination will be crucial in catalyzing uptake.

Financial Trajectory and Revenue Outlook

1. Revenue Drivers

Lurbinectedin’s initial revenues are expected to stem from its approved use in SCLC, with projections influenced by treatment prevalence, dosing regimens, and market penetration rates. The incidence of ES-SCLC globally suggests a sizable but limited patient population (~31,000 new cases annually in the US alone [4]), offering a near-term revenue horizon.

The pricing, aligned with other targeted oncology agents (~$10,000–$15,000 per treatment cycle), significantly influences revenue. High unmet needs in relapsed SCLC favor premium pricing strategies, although payer reimbursement negotiations could moderate this.

2. Market Penetration and Growth Assumptions

Based on early market access data and analyst forecasts, lurbinectedin could achieve a modest to moderate market share within the relapsed SCLC segment—projected estimates suggest a 15-20% uptake in initial years, increasing as evidence accumulates and additional indications are pursued.

Assuming annual sales of approximately $100–200 million in the first 3–5 years, potential expansion into combination therapies and other indications could bolster revenues. Moreover, strategic partnerships for global distribution—particularly in Europe and Asia—are likely crucial for growth.

3. Financial Risks and Opportunities

The potential for generic competition in the longer term remains remote due to lurbinectedin’s complex synthesis and patent protections. Conversely, the success of upcoming clinical trials and regulatory approvals in alternate indications represent significant upside.

Conversely, delays or failures in pivotal trials, regulatory setbacks, or unfavorable reimbursement decisions pose downside risks that could dampen the financial trajectory.

Future Outlook and Strategic Considerations

Pharma Mar’s evolving clinical strategy, including combination regimens and expansion into other thoracic and extra-thoracic cancers, positions lurbinectedin for an extended lifecycle. Integration with companion diagnostics and biomarker-driven approaches could further refine its market positioning.

Partnerships with large oncology pharmaceutical firms could accelerate global rollout, leveraging established sales and marketing channels. As the oncology landscape trends toward personalized medicine, lurbinectedin’s unique mechanism may favor its inclusion in tailored treatment protocols.

Conclusion

Lurbinectedin’s market dynamics are shaped by its targeted mechanism, unmet clinical needs in relapsed SCLC, and the evolving competitive landscape. While initial revenues are constrained by niche indications, strategic clinical development, expanding indications, and product positioning could propel its financial trajectory upward, contingent on successful regulatory milestones and market adoption.

Investors and healthcare stakeholders should monitor development pipelines, clinical trial outcomes, reimbursement developments, and competitive shifts to accurately gauge long-term value.

---

Key Takeaways

• Niche but Strategic: Lurbinectedin addresses a critical unmet need in relapsed ES-SCLC, offering a differentiated mechanism of action.
• Market Potential Expansion: Beyond SCLC, ongoing trials targeting other cancers herald growth opportunities, contingent on positive trial outcomes.
• Pricing and Reimbursement: High-cost positioning necessitates demonstrating substantial clinical benefit to secure favorable payer coverage.
• Competitive Positioning: Facing competition from immunotherapies and chemotherapies, lurbinectedin’s success depends on its clinical efficacy, safety profile, and positioning within treatment algorithms.
• Partnership and Development Strategy: Strategic collaborations and expansion into combination therapies could significantly enhance its financial trajectory over the next 5–10 years.

---

FAQs

1. What is the current FDA-approved indication for lurbinectedin?
Lurbinectedin is FDA-approved for adult patients with relapsed small cell lung cancer (SCLC), specifically those with disease progression on or after platinum-based chemotherapy [1].

2. How does lurbinectedin compare to existing therapies for relapsed SCLC?
Its novel mechanism and clinical efficacy in refractory cases distinguish lurbinectedin from traditional agents like topotecan, offering improved response rates and tolerability in certain patient populations [2].

3. Are there ongoing trials that could expand lurbinectedin’s indications?
Yes, trials are investigating its use in ovarian, breast, and mesothelioma cancers, either as monotherapy or in combination, which could broaden its market footprint [3].

4. What are the main factors influencing lurbinectedin’s market adoption?
Clinical efficacy data, safety profile, reimbursement policies, clinician familiarity, and competition from immunotherapies and combination regimens primarily influence adoption.

5. What is the long-term revenue outlook for lurbinectedin?
While initial revenues are modest due to its niche indication, expansion into new indications and combination therapies, coupled with strategic partnerships, could significantly enhance its financial trajectory over the next decade.

---

References

1. US Food and Drug Administration. FDA approves Zepzelca for small cell lung cancer. 2020.
2. FDA Briefing Document. Zepzelca (lurbinectedin) Approval Summary. 2020.
3. Pharma Mar. ClinicalTrials.gov. NCT04682953 – Lurbinectedin for ovarian cancer.
4. American Cancer Society. Key Statistics for Small Cell Lung Cancer. 2022.